CN112789276A - 镇痛化合物、其制法与医药上的用途 - Google Patents

镇痛化合物、其制法与医药上的用途 Download PDF

Info

Publication number
CN112789276A
CN112789276A CN202080003851.5A CN202080003851A CN112789276A CN 112789276 A CN112789276 A CN 112789276A CN 202080003851 A CN202080003851 A CN 202080003851A CN 112789276 A CN112789276 A CN 112789276A
Authority
CN
China
Prior art keywords
alkyl
ring
substituted
unsubstituted
membered saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080003851.5A
Other languages
English (en)
Inventor
刘力锋
胡斌
谢婧
石晓永
赵金柱
何宛
郭淑春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Original Assignee
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yangtze River Pharmaceutical Group Co Ltd, Shanghai Haiyan Pharmaceutical Technology Co Ltd filed Critical Yangtze River Pharmaceutical Group Co Ltd
Publication of CN112789276A publication Critical patent/CN112789276A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及双杂环甲基乙胺取代的氧杂螺环衍生物、其制法与医药上的用途。具体地，本发明公开了式(I)化合物或其药学上可接受的盐、立体异构体或溶剂化物，及其制备方法和应用，式中各基团的定义详见说明书和权利要求书。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202080003851.5A 2019-08-14 2020-04-14 镇痛化合物、其制法与医药上的用途 Pending CN112789276A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910749799 2019-08-14
CN2019107497997 2019-08-14
PCT/CN2020/084773 WO2021027304A1 (zh) 2019-08-14 2020-04-14 镇痛化合物、其制法与医药上的用途

Publications (1)

Publication Number Publication Date
CN112789276A true CN112789276A (zh) 2021-05-11

Family

ID=74569509

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080003851.5A Pending CN112789276A (zh) 2019-08-14 2020-04-14 镇痛化合物、其制法与医药上的用途

Country Status (2)

Country Link
CN (1) CN112789276A (zh)
WO (1) WO2021027304A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230162058A (ko) * 2021-03-29 2023-11-28 슈징 바이오파마 컴퍼니 리미티드 스피로 함유 유도체, 이를 위한 제조 방법 및 이의 용도
WO2024067542A1 (zh) * 2022-09-27 2024-04-04 上海枢境生物科技有限公司 一种含螺环类衍生物的盐、晶型及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017063509A1 (zh) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用
CN106588899A (zh) * 2015-10-15 2017-04-26 江苏恒瑞医药股份有限公司 吡啶基取代的6‑氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用
WO2018188641A1 (zh) * 2017-04-14 2018-10-18 江苏恒瑞医药股份有限公司 一种mor激动剂与kor激动剂的药物组合物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017063509A1 (zh) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用
CN106588899A (zh) * 2015-10-15 2017-04-26 江苏恒瑞医药股份有限公司 吡啶基取代的6‑氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用
WO2018188641A1 (zh) * 2017-04-14 2018-10-18 江苏恒瑞医药股份有限公司 一种mor激动剂与kor激动剂的药物组合物及其用途

Also Published As

Publication number Publication date
WO2021027304A1 (zh) 2021-02-18

Similar Documents

Publication Publication Date Title
AU2008312540B2 (en) Inhibitors of c-fms kinase
CN111662284B (zh) 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
TWI751163B (zh) Ｆｇｆｒ４抑制劑、其製備方法和應用
CN114269751B (zh) 光学纯的氧杂螺环取代的吡咯并吡唑衍生物、其制法与医药上的用途
JP7442652B2 (ja) アザビシクロ置換オキサスピロ環誘導体、その調製方法及び医学的使用
AU2005282721A1 (en) 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
KR20050071471A (ko) 티오펜 화합물
CN112789276A (zh) 镇痛化合物、其制法与医药上的用途
CN112778183B (zh) 含氮环类衍生物调节剂、其制备方法和应用
CN113214264B (zh) 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途
JP6900406B2 (ja) Ａｋｔ阻害剤としてのジヒドロピラゾロアゼピン系化合物
CN114085220B (zh) 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
KR20230147159A (ko) 헤테로고리로 치환된 메탄온계 유도체, 이의 조성물 및 의약적 용도
JP5723364B2 (ja) 渡環型ジヒドロピロロ［２，１−ａ］イソキノリン
RU2800295C1 (ru) Оптически чистое оксаспиро-замещенное производное пирролопиразола, способ его получения и его фармацевтическое применение
RU2800296C1 (ru) Оксаспиро-производное, замещенное по азабициклическому кольцу, способ его получения и его медицинское применение
CN113727984A (zh) 大环类衍生物、及其制备方法和用途
WO2024046454A1 (zh) 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用
CN112334465A (zh) 三环取代的氧杂螺环衍生物、其制法与医药上的用途
CN116023367A (zh) 含四氢呋喃多环类衍生物、其药学上可接受的盐及其制备方法和应用
CN116249691A (zh) 双环类衍生物调节剂、其制备方法和应用
AU2013203813B2 (en) Inhibitors of C-FMS kinase
CN116262753A (zh) 一种新颖的pim激酶抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination